Metformin’s effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK/SERCA2b pathway

Metformin’s effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK/SERCA2b pathway

IntroductionMetformin has shown benefits in treating metabolic dysfunction-associated steatotic liver disease (MASLD), but its mechanisms remain unclear. This study investigates miR-200a-5p’s role in the AMPK/SERCA2b pathway to reduce liver fat accumulation and ER stress in MASLD.MethodsA PA cell mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Hang Chen, Minshan Huang, Dan Zhang, Hui Wang, Da Wang, Mengwei Li, Xianmei Wang, Rui Zhu, Jianjun Liu, Lanqing Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
MASLD
metformin
miR-200a-5p
AMPK
SERCA2b
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1477212/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1477212/full

Similar Items